Market Cap (In PLN)
51.99 Million
Revenue (In PLN)
46.78 Million
Net Income (In PLN)
586 Thousand
Avg. Volume
9538.00
- Currency
- PLN
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 11.35-20.5
- PE
- -155.0
- EPS
- -0.08
- Beta Value
- -2.419
- ISIN
- PLBIOMX00015
- CUSIP
- -
- CIK
- -
- Shares
- 4193120.0
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Mr. Lukasz Urban
- Employee Count
- -
- Website
- https://www.biomaxima.com
- Ipo Date
- 2010-07-21
- Details
- BioMaxima S.A. manufactures and distributes reagents for in vitro diagnostics in Poland. Its primary products include diagnostic reagents and analyzers for clinical chemistry; rapid tests and readers for detecting infectious diseases, cancer markers, cardiac markers, and drugs of abuse; urine analysis systems; hematology analyzers and reagents; ionselective analyzers and reagents; reagents and immunological analyzers of cardiac markers; glucometers for professional use; and analyzers for gasometric tests and critical blood parameters tests. The company also provides surfaces and air controls; antibiotics discs and MIC strips; and chromogenic, dehydrated, and prepared culture media; and additives and supplements for media. It supplies its products to approximately 2,000 laboratories in Poland, as well as exports in the international markets. BioMaxima S.A. was founded in 2002 and is based in Lublin, Poland.
More Stocks
-
KRU
-
CLAClaranova SE
CLA
-
USCTFRoth CH Acquisition Co.
USCTF
-
KEX
-
BLGOBioLargo, Inc.
BLGO
-
MFC
-
0R3E
-
AEO